tretinoin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
retinol derivatives 2722 302-79-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tretinoin potassium
  • trans-Retinoic acid
  • tretinoin sodium
  • retinoic acid
  • tretinoin
An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).
  • Molecular weight: 300.44
  • Formula: C20H28O2
  • CLOGP: 6.74
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 1
  • TPSA: 37.30
  • ALOGS: -4.80
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.70 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Oct. 20, 1971 FDA VALEANT INTL

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Differentiation syndrome 792.01 16.14 135 8037 968 63479882
Blepharospasm 260.21 16.14 73 8099 5923 63474927
Taste disorder 197.34 16.14 72 8100 13590 63467260
Epilepsy 152.87 16.14 73 8099 26992 63453858
Idiopathic intracranial hypertension 137.74 16.14 38 8134 2893 63477957
Product use in unapproved indication 131.03 16.14 137 8035 178943 63301907
Intracranial pressure increased 96.20 16.14 33 8139 5194 63475656
Migraine 86.27 16.14 85 8087 103261 63377589
Gastrooesophageal reflux disease 86.11 16.14 82 8090 95557 63385293
Memory impairment 78.32 16.14 81 8091 104177 63376673
Hypoaesthesia 78.05 16.14 102 8070 168291 63312559
Leukaemia recurrent 75.29 16.14 20 8152 1318 63479532
Paraesthesia 61.98 16.14 88 8084 156878 63323972
Abdominal pain upper 46.61 16.14 90 8082 206354 63274496
Dry skin 45.95 16.14 46 8126 56841 63424009
Haematopoietic neoplasm 43.01 16.14 7 8165 36 63480814
Abortion spontaneous 41.54 16.14 40 8132 47155 63433695
Polyarteritis nodosa 34.95 16.14 8 8164 283 63480567
Lower respiratory tract infection fungal 33.74 16.14 8 8164 331 63480519
Dysphoria 32.99 16.14 15 8157 4951 63475899
Skin warm 31.59 16.14 15 8157 5461 63475389
Haemorrhagic diathesis 31.44 16.14 14 8158 4401 63476449
Off label use 30.81 16.14 169 8003 674293 62806557
Papilloedema 29.62 16.14 13 8159 3947 63476903
Xerosis 29.52 16.14 9 8163 973 63479877
Myelodysplastic syndrome 26.72 16.14 20 8152 16734 63464116
Disseminated intravascular coagulation 26.57 16.14 21 8151 19030 63461820
VIth nerve paralysis 26.27 16.14 8 8164 862 63479988
Chloroma 25.57 16.14 6 8166 237 63480613
Appetite disorder 24.73 16.14 14 8158 7307 63473543
Chromosomal deletion 24.40 16.14 5 8167 104 63480746
Arthritis infective 23.55 16.14 13 8159 6465 63474385
Dermatitis atopic 23.52 16.14 15 8157 9709 63471141
Skin exfoliation 22.91 16.14 28 8144 43074 63437776
Acne 22.90 16.14 21 8151 23272 63457578
Neutropenic sepsis 22.67 16.14 18 8154 16420 63464430
Drug intolerance 22.66 16.14 89 8083 308572 63172278
Vomiting 22.08 16.14 135 8037 559482 62921368
Acute myeloid leukaemia 22.00 16.14 18 8154 17129 63463721
Pain 21.71 16.14 166 8006 740462 62740388
Oesophageal mass 21.08 16.14 4 8168 55 63480795
Gambling 20.34 16.14 5 8167 241 63480609
Myocarditis 20.30 16.14 14 8158 10311 63470539
Thinking abnormal 19.92 16.14 14 8158 10629 63470221
Sweat gland tumour 18.48 16.14 4 8168 109 63480741
Contraindicated product administered 18.35 16.14 3 8169 217645 63263205
Arthropathy 18.17 16.14 4 8168 234788 63246062
Tenderness 17.74 16.14 18 8154 22560 63458290
Febrile neutropenia 16.88 16.14 43 8129 118406 63362444
Application site dryness 16.79 16.14 4 8168 169 63480681
Erythema 16.55 16.14 55 8117 175696 63305154

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Differentiation syndrome 979.14 26.54 157 2671 1281 34952822
Idiopathic intracranial hypertension 203.09 26.54 37 2791 664 34953439
Hyperleukocytosis 121.75 26.54 29 2799 1973 34952130
Electrocardiogram QT prolonged 109.00 26.54 57 2771 40895 34913208
Haematopoietic neoplasm 82.61 26.54 12 2816 44 34954059
Acute myeloid leukaemia 77.44 26.54 35 2793 18235 34935868
Product use in unapproved indication 75.92 26.54 68 2760 117431 34836672
Leukaemia recurrent 70.85 26.54 18 2810 1597 34952506
Cytogenetic abnormality 54.58 26.54 13 2815 882 34953221
Hypokalaemia 46.25 26.54 38 2790 58176 34895927
Scrotal ulcer 45.51 26.54 10 2818 473 34953630
Hypomagnesaemia 40.46 26.54 24 2804 21827 34932276
Myelodysplastic syndrome 35.30 26.54 21 2807 19187 34934916
Febrile neutropenia 35.21 26.54 49 2779 136800 34817303
Neutropenia 34.33 26.54 52 2776 156726 34797377
IIIrd nerve paralysis 34.01 26.54 8 2820 514 34953589
Lymphopenia 30.38 26.54 18 2810 16317 34937786
Large granular lymphocytosis 28.84 26.54 6 2822 218 34953885
Jugular vein thrombosis 28.70 26.54 9 2819 1706 34952397
Extremity necrosis 27.47 26.54 9 2819 1963 34952140
Acute febrile neutrophilic dermatosis 26.75 26.54 8 2820 1295 34952808

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Differentiation syndrome 1705.40 16.46 288 8840 2236 79733024
Idiopathic intracranial hypertension 261.44 16.46 63 9065 3159 79732101
Blepharospasm 179.49 16.46 53 9075 5798 79729462
Myelodysplastic syndrome transformation 160.32 16.46 32 9096 657 79734603
Product use in unapproved indication 139.60 16.46 157 8971 250202 79485058
Taste disorder 127.90 16.46 53 9075 15770 79719490
Hyperleukocytosis 127.33 16.46 34 9094 2576 79732684
Leukaemia recurrent 106.82 16.46 30 9098 2744 79732516
Intracranial pressure increased 85.00 16.46 33 9095 8289 79726971
Acute myeloid leukaemia 78.25 16.46 47 9081 30838 79704422
Epilepsy 78.05 16.46 52 9076 40808 79694452
Electrocardiogram QT prolonged 76.30 16.46 71 9057 90315 79644945
Haematopoietic neoplasm 72.22 16.46 12 9116 82 79735178
Cytogenetic abnormality 66.15 16.46 17 9111 1108 79734152
Migraine 61.19 16.46 62 9066 87431 79647829
Myelodysplastic syndrome 56.50 16.46 38 9090 30263 79704997
Abortion spontaneous 55.01 16.46 37 9091 29470 79705790
Hypoaesthesia 50.91 16.46 81 9047 179271 79555989
Gastrooesophageal reflux disease 48.96 16.46 60 9068 104186 79631074
Second primary malignancy 44.74 16.46 25 9103 14325 79720935
Hypercalcaemia 44.13 16.46 36 9092 38394 79696866
Memory impairment 44.11 16.46 59 9069 111675 79623585
Off label use 40.93 16.46 208 8920 907007 78828253
Febrile neutropenia 39.72 16.46 84 9044 230915 79504345
Papilloedema 37.63 16.46 17 9111 6216 79729044
Paraesthesia 37.38 16.46 70 9058 176253 79559007
Disseminated intravascular coagulation 35.84 16.46 31 9097 35811 79699449
Myocarditis 35.20 16.46 25 9103 21708 79713552
Neutropenia 34.61 16.46 91 9037 287619 79447641
Dysphoria 32.08 16.46 14 9114 4720 79730540
Polyarteritis nodosa 30.90 16.46 8 9120 537 79734723
Chloroma 28.16 16.46 8 9120 762 79734498
Lower respiratory tract infection fungal 27.03 16.46 8 9120 880 79734380
Acute promyelocytic leukaemia 26.86 16.46 9 9119 1482 79733778
Abdominal pain upper 26.09 16.46 70 9058 223749 79511511
Haemorrhagic diathesis 25.75 16.46 13 9115 6071 79729189
Dry skin 25.44 16.46 35 9093 67960 79667300
Gastrointestinal toxicity 24.93 16.46 14 9114 8095 79727165
Acute febrile neutrophilic dermatosis 24.78 16.46 11 9117 3861 79731399
IIIrd nerve paralysis 24.70 16.46 8 9120 1185 79734075
Hypomagnesaemia 23.64 16.46 28 9100 46883 79688377
Large granular lymphocytosis 23.56 16.46 6 9122 377 79734883
White blood cell count increased 22.94 16.46 35 9093 74598 79660662
Scrotal ulcer 22.87 16.46 6 9122 424 79734836
Chromosomal deletion 22.82 16.46 5 9123 163 79735097
Appetite disorder 22.81 16.46 13 9115 7726 79727534
VIth nerve paralysis 22.29 16.46 8 9120 1616 79733644
Ciliary body melanoma 22.15 16.46 3 9125 3 79735257
Dermatitis atopic 22.14 16.46 14 9114 10042 79725218
Skin warm 21.89 16.46 12 9116 6620 79728640
Photophobia 21.01 16.46 18 9110 20510 79714750
Oesophageal mass 20.69 16.46 4 9124 69 79735191
Extremity necrosis 20.29 16.46 9 9119 3152 79732108
Bone marrow necrosis 20.14 16.46 5 9123 283 79734977
Jugular vein thrombosis 20.10 16.46 10 9118 4528 79730732
Drug intolerance 19.94 16.46 71 9057 264048 79471212
Acute myeloid leukaemia recurrent 19.71 16.46 9 9119 3374 79731886
Arthritis infective 19.43 16.46 12 9116 8259 79727001
Endocarditis 19.06 16.46 13 9115 10584 79724676
Tenderness 18.83 16.46 18 9110 23624 79711636
Thinking abnormal 18.73 16.46 14 9114 13147 79722113
Completed suicide 18.45 16.46 3 9125 245764 79489496
Haemorrhage 17.84 16.46 35 9093 91083 79644177
Pericardial effusion 17.59 16.46 24 9104 46213 79689047
Pulmonary tuberculosis 17.44 16.46 11 9117 7854 79727406
Gelatinous transformation of the bone marrow 17.42 16.46 3 9125 26 79735234
Septic embolus 17.00 16.46 7 9121 2044 79733216

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D10AD01 DERMATOLOGICALS
ANTI-ACNE PREPARATIONS
ANTI-ACNE PREPARATIONS FOR TOPICAL USE
Retinoids for topical use in acne
ATC D10AD51 DERMATOLOGICALS
ANTI-ACNE PREPARATIONS
ANTI-ACNE PREPARATIONS FOR TOPICAL USE
Retinoids for topical use in acne
ATC L01XF01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Retinoids for cancer treatment
FDA CS M0018962 Retinoids
CHEBI has role CHEBI:22586 antioxidants
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:50176 keratolytic drugs
CHEBI has role CHEBI:62488 signal molecules
CHEBI has role CHEBI:63794 retinoid X receptor agonists
CHEBI has role CHEBI:67079 anti-inflammatory agents
CHEBI has role CHEBI:67198 retinoic acid receptor agonists
CHEBI has role CHEBI:67199 activator protein-1 antagonists
CHEBI has role CHEBI:77746 Homo sapiens metabolite
FDA EPC N0000175607 Retinoid
MeSH PA D000970 Antineoplastic Agents
MeSH PA D003879 Dermatologic Agents
MeSH PA D007641 Keratolytic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chloasma indication 36209000
Acne vulgaris indication 88616000
Acute promyelocytic leukemia, FAB M3 indication 110004001
Hyperkeratosis indication 396228006
Facial Fine Wrinkling indication
Solar Lentigines indication
Fine Wrinkling indication
Severe Recalcitrant Nodular Acne indication
Kaposi's Sarcoma Skin Lesions indication
Mottle Hyperpigmentation indication
Keratosis follicularis off-label use 48611009 DOID:2734
Lamellar ichthyosis off-label use 205550003
Plane wart off-label use 240539000
Primary cutaneous T-cell lymphoma off-label use 400122007
Severe Recalcitrant Nodular Rosacea off-label use
Osteomalacia contraindication 4598005 DOID:10573
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Rectal hemorrhage contraindication 12063002
Hypercholesterolemia contraindication 13644009
Hearing loss contraindication 15188001
Agranulocytosis contraindication 17182001 DOID:12987
Myocardial infarction contraindication 22298006 DOID:5844
Sunburn contraindication 23346002
Atopic dermatitis contraindication 24079001 DOID:3310
Inflammatory bowel disease contraindication 24526004 DOID:0050589
Crohn's disease contraindication 34000006
Depressive disorder contraindication 35489007
Eczema contraindication 43116000
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Vitiligo contraindication 56727007 DOID:12306
Anorexia nervosa contraindication 56882008 DOID:8689
Tinnitus contraindication 60862001
Corneal opacity contraindication 64634000
Ulcerative colitis contraindication 64766004 DOID:8577
Osteoporosis contraindication 64859006 DOID:11476
Benign intracranial hypertension contraindication 68267002 DOID:11459
Psychotic disorder contraindication 69322001
Diabetes mellitus contraindication 73211009 DOID:9351
Disorder of bone contraindication 76069003 DOID:0080001
Congenital neutropenia contraindication 89655007
Kidney disease contraindication 90708001 DOID:557
Venous thrombosis contraindication 111293003
Leukocytosis contraindication 111583006
Mycosis fungoides contraindication 118618005
Inflammatory disease of liver contraindication 128241005
Bleeding contraindication 131148009
Liver function tests abnormal contraindication 166603001
Acute pancreatitis contraindication 197456007 DOID:2913
Disease of liver contraindication 235856003 DOID:409
Telangiectasia disorder contraindication 247479008
Dyspnea contraindication 267036007
Edema contraindication 267038008
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Keratoconjunctivitis sicca contraindication 302896008 DOID:12895
Neutropenic disorder contraindication 303011007 DOID:1227
Pericardial effusion contraindication 373945007 DOID:118
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Fever contraindication 386661006
Pseudomembranous enterocolitis contraindication 397683000
Atrophoderma contraindication 399979006
Peripheral vascular disease contraindication 400047006
Severe diarrhea contraindication 409587002
Breastfeeding (mother) contraindication 413712001
Obesity contraindication 414916001 DOID:9970
Denuded skin contraindication 418242004
Retinoic acid syndrome contraindication 450887006
Pulmonary Infiltrates contraindication
Pleural Effusions contraindication
Predisposition To Hypertriglyceridemia contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.17 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
3%;0.1% TWYNEO GALDERMA LABS LP N214902 July 26, 2021 RX CREAM TOPICAL 9868103 Aug. 8, 2028 TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
3%;0.1% TWYNEO GALDERMA LABS LP N214902 July 26, 2021 RX CREAM TOPICAL 10653899 Dec. 30, 2030 TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
3%;0.1% TWYNEO GALDERMA LABS LP N214902 July 26, 2021 RX CREAM TOPICAL 10420743 July 12, 2038 TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
0.05% ALTRENO DOW PHARM N209353 Aug. 23, 2018 RX LOTION TOPICAL 10653656 Aug. 22, 2038 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER
0.05% ALTRENO DOW PHARM N209353 Aug. 23, 2018 RX LOTION TOPICAL 11324710 Aug. 22, 2038 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
3%;0.1% TWYNEO GALDERMA LABS LP N214902 July 26, 2021 RX CREAM TOPICAL July 26, 2024 NEW COMBINATION

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Retinoic acid receptor beta Nuclear hormone receptor AGONIST EC50 6.70 WOMBAT-PK CHEMBL
Retinoic acid receptor gamma Nuclear hormone receptor AGONIST EC50 6.70 WOMBAT-PK CHEMBL
Retinoic acid receptor alpha Nuclear hormone receptor AGONIST EC50 6.70 WOMBAT-PK CHEMBL
Nuclear receptor ROR-alpha Nuclear hormone receptor IC50 6.70 CHEMBL
Retinoic acid receptor RXR-alpha Nuclear hormone receptor Ki 9.40 CHEMBL
Retinoic acid receptor RXR-beta Nuclear hormone receptor Ki 9.30 CHEMBL
Retinoic acid receptor RXR-gamma Nuclear hormone receptor Ki 8.85 CHEMBL
Peroxisome proliferator-activated receptor delta Nuclear hormone receptor AGONIST Kd 7.80 IUPHAR
Nuclear receptor ROR-beta Nuclear hormone receptor ANTAGONIST IC50 9.82 IUPHAR
Nuclear receptor ROR-gamma Nuclear hormone receptor IC50 6.70 CHEMBL
Mitogen-activated protein kinase 1 Kinase IC50 6.24 DRUG MATRIX
Nuclear receptor subfamily 2 group E member 1 Nuclear hormone receptor AGONIST EC50 5.74 IUPHAR
Amyloid beta A4 protein Unclassified IC50 6.75 CHEMBL
Nuclear receptor subfamily 2 group C member 2 Nuclear other AGONIST EC50 4.62 IUPHAR
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 Unclassified IC50 6.09 CHEMBL
5-hydroxytryptamine receptor 2B GPCR Ki 6.64 DRUG MATRIX
Alpha-synuclein Transporter IC50 5.52 CHEMBL
Adenosine receptor A3 GPCR Ki 5.53 DRUG MATRIX
11-cis retinol dehydrogenase Enzyme Ki 7 WOMBAT-PK
Cellular retinoic acid-binding protein 1 Cytosolic other IC50 6.43 CHEMBL
Retinoic acid receptor RXR-beta Transcription factor Kd 6.51 CHEMBL
Retinoic acid receptor RXR-gamma Transcription factor Kd 6.46 CHEMBL
Cellular retinoic acid-binding protein 1 Cytosolic other Kd 9.40 CHEMBL
Cellular retinoic acid-binding protein 2 Cytosolic other Kd 8.70 CHEMBL
Retinoic acid receptor alpha Transcription factor Kd 7.82 CHEMBL
Retinoic acid receptor RXR-alpha Transcription factor Kd 6 CHEMBL
Retinoic acid receptor beta Transcription factor Kd 7.89 CHEMBL
Retinoic acid receptor gamma Transcription factor Kd 7.74 CHEMBL
Indoleamine 2,3-dioxygenase 2 Enzyme IC50 4.54 CHEMBL

External reference:

IDSource
4018550 VUID
N0000146871 NUI
D00094 KEGG_DRUG
4018550 VANDF
C0040845 UMLSCUI
CHEBI:15367 CHEBI
3KV PDB_CHEM_ID
CHEMBL38 ChEMBL_ID
DB00755 DRUGBANK_ID
D014212 MESH_DESCRIPTOR_UI
444795 PUBCHEM_CID
2644 IUPHAR_LIGAND_ID
2875 INN_ID
5688UTC01R UNII
10753 RXNORM
46802 MMSL
5610 MMSL
d03863 MMSL
001954 NDDF
387305002 SNOMEDCT_US
54972005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Altreno HUMAN PRESCRIPTION DRUG LABEL 1 0187-0005 LOTION 0.50 mg TOPICAL NDA 24 sections
Retin-A MICRO HUMAN PRESCRIPTION DRUG LABEL 1 0187-5140 GEL 1 mg TOPICAL NDA 26 sections
Retin-A MICRO HUMAN PRESCRIPTION DRUG LABEL 1 0187-5140 GEL 1 mg TOPICAL NDA 26 sections
Retin-A MICRO HUMAN PRESCRIPTION DRUG LABEL 1 0187-5140 GEL 1 mg TOPICAL NDA 26 sections
Retin-A MICRO HUMAN PRESCRIPTION DRUG LABEL 1 0187-5144 GEL 0.40 mg TOPICAL NDA 26 sections
Retin-A MICRO HUMAN PRESCRIPTION DRUG LABEL 1 0187-5144 GEL 0.40 mg TOPICAL NDA 26 sections
Retin-A MICRO HUMAN PRESCRIPTION DRUG LABEL 1 0187-5144 GEL 0.40 mg TOPICAL NDA 26 sections
Retin-A MICRO HUMAN PRESCRIPTION DRUG LABEL 1 0187-5146 GEL 0.60 mg TOPICAL NDA 26 sections
Retin-A MICRO HUMAN PRESCRIPTION DRUG LABEL 1 0187-5146 GEL 0.60 mg TOPICAL NDA 26 sections
Retin-A MICRO HUMAN PRESCRIPTION DRUG LABEL 1 0187-5146 GEL 0.60 mg TOPICAL NDA 26 sections
Retin-A MICRO HUMAN PRESCRIPTION DRUG LABEL 1 0187-5148 GEL 0.80 mg TOPICAL NDA 26 sections
Retin-A MICRO HUMAN PRESCRIPTION DRUG LABEL 1 0187-5148 GEL 0.80 mg TOPICAL NDA 26 sections
Retin-A MICRO HUMAN PRESCRIPTION DRUG LABEL 1 0187-5148 GEL 0.80 mg TOPICAL NDA 26 sections
Renova HUMAN PRESCRIPTION DRUG LABEL 1 0187-5150 CREAM 0.20 mg TOPICAL NDA 25 sections
Retin-A HUMAN PRESCRIPTION DRUG LABEL 1 0187-5160 CREAM 0.25 mg TOPICAL NDA 21 sections
Retin-A HUMAN PRESCRIPTION DRUG LABEL 1 0187-5160 CREAM 0.25 mg TOPICAL NDA 21 sections
Retin-A HUMAN PRESCRIPTION DRUG LABEL 1 0187-5162 CREAM 0.50 mg TOPICAL NDA 21 sections
Retin-A HUMAN PRESCRIPTION DRUG LABEL 1 0187-5162 CREAM 0.50 mg TOPICAL NDA 21 sections
Retin-A HUMAN PRESCRIPTION DRUG LABEL 1 0187-5164 CREAM 1 mg TOPICAL NDA 21 sections
Retin-A HUMAN PRESCRIPTION DRUG LABEL 1 0187-5164 CREAM 1 mg TOPICAL NDA 21 sections
Retin-A HUMAN PRESCRIPTION DRUG LABEL 1 0187-5170 GEL 0.25 mg TOPICAL NDA 21 sections
Retin-A HUMAN PRESCRIPTION DRUG LABEL 1 0187-5170 GEL 0.25 mg TOPICAL NDA 21 sections
Retin-A HUMAN PRESCRIPTION DRUG LABEL 1 0187-5172 GEL 0.10 mg TOPICAL NDA 21 sections
Retin-A HUMAN PRESCRIPTION DRUG LABEL 1 0187-5172 GEL 0.10 mg TOPICAL NDA 21 sections
TWYNEO HUMAN PRESCRIPTION DRUG LABEL 2 0299-5945 CREAM 1 mg TOPICAL NDA 26 sections
TWYNEO HUMAN PRESCRIPTION DRUG LABEL 2 0299-5945 CREAM 1 mg TOPICAL NDA 26 sections
TRI-LUMA HUMAN PRESCRIPTION DRUG LABEL 3 0299-5950 CREAM 0.50 mg TOPICAL NDA 24 sections
TRI-LUMA HUMAN PRESCRIPTION DRUG LABEL 3 0299-5950 CREAM 0.50 mg TOPICAL NDA 24 sections
TRI-LUMA HUMAN PRESCRIPTION DRUG LABEL 3 0299-5950 CREAM 0.50 mg TOPICAL NDA 24 sections
Avita HUMAN PRESCRIPTION DRUG LABEL 1 0378-6140 GEL 0.25 mg TOPICAL NDA 22 sections